Osteopontin as a predictor of adverse events in patients with comorbid pathology

Information about the results of the examination of 78 women aged 50 to 65 years is given. The nature of comorbid pathology was studied: chronic heart failure, type 2 diabetes mellitus and osteoporosis. It has been established that osteopontin is an independent risk factor for the development of adverse cardiovascular events and bone fractures in women with comorbid pathology. During 36 months of prospective follow-up, patients with comorbid pathology and OPN level >21.4 ng/ml were significantly more likely to have adverse cardiovascular events and osteoporotic fractures. In patients of the 2nd group with an AKI level of >21.4 ng/ml compared with the group with an AKI concentration of ≤21.4 ng/ml, the risk of cumulative (combined frequency of the combined end point of cardiovascular events) was increased (OR = 6.200 [95% CI 2.258-17.024; p=0.001]). Separate analysis showed a significant increase in the risk of adverse events within 36 months at an AKI concentration of >21.4 ng/ml: progression of CHF (OR=4.073 [95% CI 1.575-10.531; p=0.023]) and osteoporotic bone fractures (OR=0 .81 [95% CI 0.72-0.90; p=0.01]); risks of MI (OR=4.343 [95% CI 0.463-40.751; p=0.162]), stroke (OR=1.178 [95% CI 0.315-31.860; p=0.498]), and decompensation of CHF (OR=1.938 [95% CI 0.696-5.391; p=0.083]) increased insignificantly. The level of acute renal failure >21.4 ng/ml (sensitivity-83%, specificity-62%) makes it possible to predict the onset of adverse cardiovascular events in patients with coronary artery disease with type 2 diabetes and osteoporosis with a high probability.